Latest Bevacizumab Stories
Advances in DNA testing could open the door for more expensive cancer treatments to be approved, as well as more personalized treatment options to emerge, one expert told Telegraph Medical Correspondent Stephen Adams on Saturday. Matthew Seymour, director of the National Cancer Research Network (NCRN), told Adams that genetic testing techniques were advancing so rapidly that doctors could soon administer such an exam to find out which types of medicine would work best for them. That, in...
DALLAS, October 28, 2011 /PRNewswire/ -- ReportsnReports adds 'Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020' to its store. This report provides Hyper Acute Pancreas sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Pancreatic Cancer market....
WAYNE, N.J., Oct. 26, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today announced results from its Phase III trial evaluating its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies: The trial met its primary endpoint of statistically significant improvement in overall survival. This is the result of a pre-planned interim analysis conducted by an...
DALLAS, October 20, 2011 /PRNewswire/ -- ReportsnReports adds multiple pharmaceutical reports on Drugs for Ovarian Cancer and Breast Cancer with their market analysis and forecasts to 2015, 2017 & 2020 (different for different drugs). A part of these research studies covers sales forecasts for US, EU, Japan and the targeted geographies, detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during...
NEW YORK, Oct. 19, 2011 /PRNewswire/ -- It is well known that ophthalmologists around the world often prescribe Avastin (bevacizumab) off-label for wet age-related macular degeneration (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to cost and the belief that the two have similar efficacy. AMD Alliance International (AMDAI) is calling for ophthalmologists to stop this practice in light of a concerning surge in eye infections over the past month in patients being...
Older people are at increased risk of several eye diseases, including age-related macular degeneration (AMD), cataracts, and glaucoma. AMD can cause profound loss of central vision due to the breakdown of the eye's light-sensing cells in the retina. Cataracts cloud vision through clumping of proteins in the eye's lens. Glaucoma damages the optic nerve often due to increased pressure in the eye. The increase in type 2 diabetes, which is more common in older Americans and especially minorities,...
REDWOOD CITY, Calif., Oct. 3, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a privately-held company developing novel therapeutics that target cancer stem cells, today announced that Jakob Dupont, M.D., formerly Global Medical Director for Avastin(®) (bevacizumab) at Genentech, a member of the Roche Group, has joined the company as Vice President, Clinical Research. At OncoMed, Dr. Dupont will be part of a global development team advancing multiple anti-cancer stem cell...
NEW YORK, LONDON and HAMILTON, Bermuda, Oct. 3, 2011 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") is pleased to announce the completion of enrollment into a maximum dose tolerance study of investigational product Xerecept® (corticorelin acetate) in pediatric patients who were dependent on chronic Decadron (dexamethasone) dosing due to peritumoral brain edema associated with cerebral tumors. In the open label study, 100% of the subjects showed substantive...
MELBOURNE, Australia, Sept. 30, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer. VGX-100 is a human antibody...
OCALA, Fla. and THE WOODLANDS, Texas, Sept. 28, 2011 /PRNewswire/ -- Thomas Cartwright, M.D., medical oncologist with Ocala Oncology and a member of the Pharmacy & Therapeutics (P&T) Committee and Pathways Task Force Committee, physician advisory groups within The US Oncology Network, presented findings from a study titled "Survival outcomes with use of bevacizumab beyond progression (BBP) in metastatic colorectal cancer (MCRC) patients (Pts)" at 9:30am on September 25 during the...
